AstraZeneca to divest Nordic over-the-counter portfolio
- Details
- Category: AstraZeneca
AstraZeneca has announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca's strategy to focus on innovation in prescription medicines.
Pfizer withdraws its application to change the marketing authorisation for Viagra
- Details
- Category: Pfizer
The European Medicines Agency (EMEA) has been formally notified by Pfizer Limited of its decision to withdraw its application for a change to the marketing authorisation for the medicine Viagra (sildenafil) 50 mg film-coated tablets.
AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation
- Details
- Category: AstraZeneca
On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Russia has chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for primary immunization of all infants. The IPV doses are provided by M.P. Chumakov Institute of Poliomyelitis and Virus Encephalitides through a manufacturing agreement with Sanofi Pasteur.
Pfizer Launches Global Regenerative Medicine Research Unit
- Details
- Category: Pfizer
Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity that provides, to discover and develop a new generation of regenerative medicines for major medical needs.
SEROQUEL XR and SEROQUEL Approved in Europe for New Indications
- Details
- Category: AstraZeneca
AstraZeneca has announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for the treatment of major depressive episodes in bipolar disorder.
Tarceva brings new hope to patients with advanced non-small cell lung cancer
- Details
- Category: Roche
Roche has announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse.
More Pharma News ...
- Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
- CRESTOR® is in line with other marketed statins - new data from the JUPITER study
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
- AstraZeneca PLC Third Quarter and Nine Months Results 2008
- Novartis to acquire Nektar Therapeutics pulmonary business unit
- European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia